Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, MD Anderson to Evaluate Ice Cold-PCR for CTC Mutation Detection


Transgenomic and the University of Texas MD Anderson Cancer Center have initiated a collaboration to evaluate Transgenomic's mutation detection technology in cancer patients, Transgenomic said this week.

Specifically, the groups will evaluate Transgenomic's "improved and complete enrichment coamplification at lower denaturation temperature," or Ice Cold-PCR, technology to analyze DNA isolated from circulating tumor cells in blood samples from patients with advanced cancer.

The study will be supervised jointly by Filip Janku, assistant professor of investigational cancer therapeutics at MD Anderson; and by Katherine Richardson, vice president of R&D, and Marcia Lewis, vice president of biomarker development, at Transgenomic.

Janku's research interest at MD Anderson is understanding the effectiveness of targeted therapies as cancer treatments, specifically those that block mutated proteins in tumor cells, switching off key tumor growth pathways. Selecting the correct pathway-blocking drugs requires knowledge about the DNA mutations in tumor cells.

One way to do this is to isolate circulating tumor cells from a cancer patient's blood sample and analyze the cells for biomarkers. However, CTCs are extremely rare in blood and difficult to analyze using traditional genomic methods, Transgenomic said.

The company's Ice Cold-PCR technology can enrich very low levels of mutant DNA in order to detect these mutations, according to the company. As such, the collaborators will attempt to use the technique to determine the presence or absence of biomarkers before, during, and after targeted therapy, which could guide a clinician on the effectiveness of specific cancer treatments, cancer relapse, or the appearance of new mutations that cause new drug resistance in a patient’s cancer, Transgenomic said.

Based in Omaha, Neb., Transgenomic originally licensed exclusive rights to the Cold-PCR technology — an early generation of the Ice Cold-PCR tech — from Dana-Farber Cancer Institute in October 2009. The company expanded its license to include Ice Cold-PCR last March (PCR Insider, 3/17/2011).

The license also allows the company and its customers to exclusively analyze Cold-PCR and Ice Cold-PCR products by pyrosequencing, Sanger sequencing, and mitochondrial DNA analysis.

In November, Transgenomic said that it had signed a worldwide collaboration and distribution agreement with Paris-based ScreenCell covering that company's isolation devices and dilution buffers for collecting CTCs in peripheral blood (PCR Insider, 11/10/2012).

Transgenomic is exclusively distributing ScreenCell's technologies in combination with its own Blocker-Sequencing cancer mutation assays, Surveyor Scan cancer mutation kits, and Wave instrument systems; and said it would eventually combine the technology with Ice Cold-PCR assays.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.